Affiliation:
1. Case Western Reserve University School of Medicine Cleveland Ohio U.S.A.
2. Department of Otolaryngology‐Head and Neck Surgery University Hospitals Cleveland Medical Center Cleveland Ohio U.S.A.
Abstract
ObjectivesIndividuals with angioedema (AE) are at high risk for airway compromise and often require endotracheal intubation. Patient factors predisposing one to airway compromise are not well described. The objective of this study is to examine whether substance use disorder (SUD) in patients with AE is associated with need for airway intervention.MethodsThis population‐based retrospective cohort study compared AE patients with SUD versus propensity‐matched control groups. Outcomes were hospitalization, intubation, and tracheotomy. Using the TriNetX National Database, this study included 28,931 patients with SUD and 117,509 patients without SUD who presented with AE.ResultsAmong patients with AE, those with each subtype of SUD (alcohol, cannabis, cocaine, tobacco, and opioids) were found to have higher risk of severe AE compared to propensity‐matched non‐SUD cohorts. Rate of hospitalization after cohort matching ranged from 20.4% for tobacco use disorder to 30.4% for cocaine use disorder, all significantly higher than the 8.0% in a population without SUD. Each SUD subtype was associated with a higher rate of intubation compared with matched non‐SUD groups, with cannabis use disorder having the highest relative risk (RR) of 3.67 (95% CI: 2.69–5.02). Tobacco (RR = 2.45, 95% CI: 1.79–3.34) and alcohol (RR = 2.82, 95% CI: 1.73–4.58) use disorders were both associated with significantly higher risk of tracheotomy.ConclusionThese data suggest that patients with SUD, regardless of subtype, and after propensity matching for demographics and comorbidities are at higher risk for adverse outcomes when presenting with AE. This study highlights clinically relevant predictors of airway compromise.Level of EvidenceLevel 3 Laryngoscope, 2024
Reference32 articles.
1. ACE inhibitor‐induced angioedema;Baram M;J Allergy Clin Immunol Pract,2013
2. ACE inhibitor‐mediated angioedema;Montinaro V;Int Immunopharmacol,2020
3. Angioedema;Hahn J;Dtsch Arztebl Int,2017
4. Epidemiology of life‐threatening and lethal anaphylaxis: a review;Moneret‐Vautrin DA;Allergy,2005
5. MRGPRX2 and adverse drug reactions;McNeil BD;Front Immunol,2021